[go: up one dir, main page]

CR8701A - Moduladores canabinoides de tetrahidro-indazol - Google Patents

Moduladores canabinoides de tetrahidro-indazol

Info

Publication number
CR8701A
CR8701A CR8701A CR8701A CR8701A CR 8701 A CR8701 A CR 8701A CR 8701 A CR8701 A CR 8701A CR 8701 A CR8701 A CR 8701A CR 8701 A CR8701 A CR 8701A
Authority
CR
Costa Rica
Prior art keywords
tetrahidro
indazol
canabinoid modulators
canabinoid
modulators
Prior art date
Application number
CR8701A
Other languages
English (en)
Inventor
Lagu Bharat
Fina Liotta
Meng Pan
Michael P Wachter
Mingde Xia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8701A publication Critical patent/CR8701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion describe un compuesto modulador canabinoide de tetrahidro-indazol de formla I: y un metodo para uso en el tratamiento, alivio o prevencion de un sindrome, trastorno o enfermedad mediado por el receptor canabinoide.
CR8701A 2004-03-24 2006-10-20 Moduladores canabinoides de tetrahidro-indazol CR8701A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55589004P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
CR8701A true CR8701A (es) 2008-11-24

Family

ID=34965110

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8701A CR8701A (es) 2004-03-24 2006-10-20 Moduladores canabinoides de tetrahidro-indazol

Country Status (22)

Country Link
US (2) US7452997B2 (es)
EP (1) EP1735286B1 (es)
JP (1) JP4825792B2 (es)
CN (1) CN1956964B (es)
AR (1) AR048341A1 (es)
AT (1) ATE540027T1 (es)
AU (1) AU2005228868B2 (es)
BR (1) BRPI0509207A (es)
CA (1) CA2561305C (es)
CR (1) CR8701A (es)
DK (1) DK1735286T3 (es)
EA (1) EA010887B1 (es)
EC (1) ECSP066877A (es)
ES (1) ES2378071T3 (es)
IL (1) IL178290A0 (es)
MX (1) MXPA06011017A (es)
NO (1) NO20064810L (es)
PL (1) PL1735286T3 (es)
PT (1) PT1735286E (es)
TW (1) TW200602324A (es)
WO (1) WO2005095353A1 (es)
ZA (1) ZA200608808B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
JP5162461B2 (ja) * 2005-09-23 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロシクロオクチルピラゾール系カンナビノイドモジュレーター
BRPI0616402A2 (pt) * 2005-09-23 2011-06-21 Janssen Pharmaceutica Nv moduladores de canabinóide de hexaidro-cicloeptapirazol
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
EP1937646A1 (en) * 2005-09-23 2008-07-02 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
WO2007038045A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica, N.V. Tetrahydro-indazolyl cannabinoid modulators
US8378096B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7795294B2 (en) 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
US20080299210A1 (en) * 2006-04-13 2008-12-04 Min Wei Stable nanosized amorphous drug
JP2010509201A (ja) * 2006-11-03 2010-03-25 グレンマーク・ファーマシューティカルズ・エスエー 新規なカンナビノイド受容体リガンド、およびこれらを含む薬剤組成物、およびこれらの調製方法
EP1935420A1 (en) * 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
KR20090120500A (ko) * 2007-03-21 2009-11-24 얀센 파마슈티카 엔.브이. Ｃｂ２ 수용체 매개 통증의 치료 방법
CN101677556A (zh) * 2007-03-21 2010-03-24 詹森药业有限公司 治疗cb2受体介导的疼痛的方法
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
JP5236748B2 (ja) * 2008-01-08 2013-07-17 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療のためのカンナビノイド受容体のリガンドとしてのプロリン類似体
US20090215850A1 (en) * 2008-02-27 2009-08-27 Mingde Xia Method for treating cb2 receptor mediated pain
WO2010034649A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
US9682940B2 (en) 2015-08-25 2017-06-20 Janssen Pharmaceutica Nv Indazole derivatives useful as CB-1 inverse agonists
CN105367498B (zh) * 2015-11-11 2019-05-17 中国农业大学 吡唑并环-3-甲酰胺类似物及其制备和应用
CN106397218A (zh) * 2016-09-04 2017-02-15 王际菊 S‑α‑环己基苯甲胺
US20210253562A1 (en) * 2018-07-03 2021-08-19 Janssen Pharmaceutica Nv Acylsufonamide compounds useful as ep3 receptor antagonists
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TWI768464B (zh) * 2019-09-12 2022-06-21 大陸商四川海思科製藥有限公司 三環吡唑衍生物及其製備
WO2021249463A1 (zh) * 2020-06-11 2021-12-16 贝达药业股份有限公司 双环化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US3895025A (en) * 1973-03-29 1975-07-15 Du Pont 2-Benzimidazolethiol preparation
US4851425A (en) * 1985-06-14 1989-07-25 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
US4861777A (en) 1987-09-11 1989-08-29 Mitsubishi Kasei Corporation Pyrazole derivative and insecticidal and miticidal composition containing the derivative as active ingredient
JPH06306053A (ja) 1993-01-29 1994-11-01 Sagami Chem Res Center ３−アゾールカルボン酸誘導体の製造方法及びその中間体
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US6410533B1 (en) * 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
JP2005527586A (ja) 2002-04-05 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド 置換アリールアミド
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
IL178290A0 (en) 2006-12-31
CA2561305A1 (en) 2005-10-13
AU2005228868A1 (en) 2005-10-13
CN1956964A (zh) 2007-05-02
ATE540027T1 (de) 2012-01-15
US20090099143A1 (en) 2009-04-16
EA200601760A1 (ru) 2007-02-27
ECSP066877A (es) 2006-11-24
DK1735286T3 (da) 2012-04-02
EA010887B1 (ru) 2008-12-30
AU2005228868B2 (en) 2012-02-09
US7452997B2 (en) 2008-11-18
PT1735286E (pt) 2012-03-05
MXPA06011017A (es) 2007-03-21
TW200602324A (en) 2006-01-16
ZA200608808B (en) 2008-06-25
AR048341A1 (es) 2006-04-19
BRPI0509207A (pt) 2007-08-28
PL1735286T3 (pl) 2012-06-29
CA2561305C (en) 2013-07-30
CN1956964B (zh) 2011-06-15
JP4825792B2 (ja) 2011-11-30
ES2378071T3 (es) 2012-04-04
EP1735286B1 (en) 2012-01-04
US20050228034A1 (en) 2005-10-13
WO2005095353A1 (en) 2005-10-13
EP1735286A1 (en) 2006-12-27
NO20064810L (no) 2006-12-22
JP2007530577A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
CR8701A (es) Moduladores canabinoides de tetrahidro-indazol
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
ECSP088315A (es) Moduladores de hexahidro-ciclooctil pirazol cannabinoide
ECSP088316A (es) Moduladores sustituidos de 3-amido-tetrahidro-indazolil cannabinoide
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CR10433A (es) Compuestos organicos y sus usos
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
TW200738270A (en) Method of treating depression using a TNFα antibody
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
EA200900767A1 (ru) Антагонистические антитела против ephb3
CR10111A (es) Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
WO2009023653A3 (en) Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
ECSP088314A (es) Moduladores de cannabinoides hexahidro-cicloheptapirazol
TW200624479A (en) Film forming material and preparation of surface relief and optically anisotropic structures by irradiating a film of the said material
CR9479A (es) Moduladores canabinoides de tetrahidrotiopirano pirazol
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
UY30972A1 (es) Moduladores cannabinoides hexahidro-ciclooctilpirazol
UY30971A1 (es) Moduladores cannabinoides hexahidro-cicloheptapirazol
CR7276A (es) Terapia de combinacion para el tratamiento del cancer